Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORY: Glofitamab Maintenance After CD19 CAR-T in RR-DLBCL
KCT0009759Phase 2Not yet recruiting
- Sponsor
- Samsung Medical Center
- Start
- Sep 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Samsung Medical Center. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on KCT0009759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009759.